Document:

Separation Agreement

  
 Exhibit 10.1

 SEPARATION AGREEMENT 

This Separation Agreement (“this Agreement”) is entered into by The Hillman Group, Inc. (“Hillman”)
and Ali Fartaj (“Employee”). 
 In consideration of the mutual promises and conditions contained in
this Agreement, Hillman and Employee agree as follows: 
 1.
Resignation.    Employee hereby resigns from his positions as an officer and employee of Hillman, effective October 22, 2010. 

2. Separation Package.    Hillman agrees to the following separation package:

  

	 	a.	 Provided Employee signs and delivers to Hillman this Agreement and does not revoke it pursuant to the provisions of section 5(b) below and provided
Employee fulfills all obligations required of Employee pursuant to section 3 below, Hillman will continue Employee’s employment with his current compensation and benefits package through October 22, 2010; however, Hillman in its sole
discretion may elect at any time during this period to terminate Employee’s job responsibilities but to continue Employee’s compensation and benefits through October 22, 2010. 

 

	 	b.	 Provided Employee on October 22, 2010 signs and delivers to Hillman the Additional Release Agreement attached hereto as Attachment A (“the
Additional Release Agreement”) and does not revoke it during the revocation period set forth in such agreement, and provided Employee fulfills all obligations required of Employee pursuant to section 3 below, Hillman will, within ten business
days of the Effective Date of the Additional Release Agreement, pay to Employee a lump sum payment of Two Hundred Thousand Dollars ($200,000), which amount shall be subject to all withholdings and deductions required by law. Employee understands and
agrees that this lump sum payment includes, and is in full settlement of, any and all amounts owed to Employee, including but not limited to: vacation pay; bonuses; severance; and any amounts Employee claims or could have claimed to be due under The
Hillman Group, Inc. Employment Agreement executed by Hillman and Employee as of April 21, 2010 (a copy of which is attached hereto as Attachment B) (“the Employment Agreement”). 

  
 Page 1 of 7

  
 3.
Employee’s Obligations.    Employee agrees to the following terms, which Employee acknowledges are material conditions to Hillman’s obligations under Section 2 above: 

 

	 	a.	 Employee agrees that, through October 22, 2010, Employee will continue to provide to Hillman Employee’s normal duties, responsibilities,
and functions as Senior Vice President of Operations. Employee agrees to cooperate fully with Hillman in bringing about a smooth transition of such duties, responsibilities, and functions to Employee’s successor(s).

  

	 	b.	 Employee agrees that the provisions of Section 6 (“Confidential Information”) of the Employment Agreement remain in full force and
effect and that Employee’s obligations under those provisions survive and are not affected in any way by this Agreement or by the Additional Release Agreement. 

 

	 	c.	 Employee and Hillman agree, subject to any obligations Employee or Hillman may have under applicable law, that they will not make or cause to be
made any statements that disparage, are inimical to, or damage the reputation of the other, or any of Hillman’s affiliated companies (including without limitation The Hillman Companies, Inc., Oak Hill Capital Partners, OHCP HM Acquisition
Corp., Oak Hill Capital Partners III, L.P., and Oak Hill Management Partners III, L.P.) or any of their respective officers, directors, shareholders, employees, agents, or representatives. Hillman agrees that, if asked by a prospective employer of
Employee, or by others, it will respond that Employee is eligible for rehire by Hillman. Employee and Hillman agree that any public relations or similar statement made or issued by Hillman about Employee will conform to the statement attached to
this Separation Agreement as Attachment 1. 

  

	 	d.	 Employee and Hillman agree that they will keep confidential the terms of this Agreement. Employee agrees that he will not disclose any of those
terms to anyone other than Employee’s attorney, tax advisors, and spouse (who must agree to keep those terms confidential), except as required by law or legal process or as necessary to enforce the terms of this Agreement.

  

	 	e.	 Employee agrees that, for a period of two years after the Effective Date of the Additional Release Agreement, Employee will not, without prior
written approval from the President of Hillman, directly or indirectly solicit any person who is an employee of Hillman to terminate his or her employment with Hillman. 

  
 Page 2 of 7

  

	 	f.	 Employee agrees that Employee will reasonably cooperate with Hillman and its legal counsel in any and all pending and future administrative and
judicial matters as to which Employee has or had any knowledge, information, or involvement. Hillman will reimburse Employee for Employee’s time and reasonable travel expenses incurred as a result of such litigation support.

 4. Release and Waiver.    Employee, for and on behalf of
Employee and Employee’s representatives, agents, next of kin, heirs, successors, and assigns, hereby releases and forever discharges Hillman and its affiliated companies (including without limitation The Hillman Companies, Inc., Oak Hill
Capital Partners, OHCP HM Acquisition Corp., Oak Hill Capital Partners III, L.P., and Oak Hill Management Partners III, L.P.) and their respective officers, directors, shareholders, employees, agents, representatives, attorneys, successors, and
assigns (“the Released Parties”) from any and all claims, causes of action, expenses including attorney fees, interest (statutory or common law), and liabilities of any kind whatsoever, whether known or unknown, or foreseen or unforeseen,
which Employee had, now has, or may ever have against the Released Parties, or any of them, arising from any act, omission, or thing that occurred before the “Effective Date” of this Agreement, including, but not limited to: claims based
on or arising out of Employee’s employment with Hillman or the termination of that employment; claims based on or arising out of the Employment Agreement; claims in tort, including without limitation, claims of libel, slander, defamation, or
invasion of privacy; claims based on contract, express or implied; claims of promissory estoppel; claims of wrongful discharge or wrongful retaliation; claims for violation of federal, state, or local laws which prohibit discrimination on the basis
of age, sex, race, ancestry, color, national origin, religion, disability, or genetic information (including without limitation claims arising under: the Age Discrimination in Employment Act of 1967, as amended, and the Older Workers Benefit
Protection Act, which prohibit age discrimination in employment; Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. §2000e et seq., which prohibits discrimination in employment based on race, color, national origin,
religion, or sex; the Americans with Disabilities Act, which prohibits discrimination in employment based on disabilities; the Employee Retirement Income Security Act, which deals with employee benefits and related matters; Ohio Revised Code Chapter
4112, which prohibits discrimination based on age, race, color, national origin, religion, sex, or disabilities; or any other federal, state, or local laws or regulations); and claims based on any other laws or court decisions affecting relations
between employers and employees. 
 The parties agree that nothing in this Section releases any of
Employee’s claims, rights, or obligations under: (1) the Stockholders Agreement among OHCP HM Acquisition Corp., Oak Hill Capital Partners III, L.P., Oak Hill Management Partners III, L.P. and certain Management Stockholders (including
Employee) dated as of May 28, 2010 or (2) the Indemnity Escrow Agreement between OHCP HM Acquisition Corp. and certain Management Stockholders (including Employee) dated as of May 28, 2010. 

  
 Page 3 of 7

  

Employee further agrees that Employee will not initiate or pursue any claims, actions, complaints, charges, or litigation
against any of the Released Parties based on or arising out of any claim released herein. If Employee institutes any claim, charge, or action that has been released herein, or is a party to any such proceeding, Employee’s claims shall be
dismissed, with prejudice, and Employee shall pay all attorney fees and costs incurred by any of the Released Parties as a result of any such action. 
 The parties recognize that nothing in this Section or in any other provision of this Agreement shall be construed to prevent Employee from filing or maintaining a charge of discrimination with the Equal
Employment Opportunity Commission or any other state or local government agency responsible for enforcing federal, state, or local anti-discrimination laws. If such a proceeding is instituted or maintained by such an agency or by Employee, all of
the covenants and waivers of Employee under this Agreement shall remain in full force and effect, and Employee shall not be entitled to (and hereby waives any right to) any relief specific to Employee, including but not limited to reinstatement,
back pay, front pay, benefits, or any damages of any kind with respect to such charge, claim or action. 

Employee understands that this Agreement resolves any and all claims, disputes, and causes of action that Employee may
have against the Released Parties, or any of them, arising out of or in any way related to Employee’s employment with Hillman or the termination of that employment or claims arising out of or in any way related to the Employment Agreement.

 5. OWBPA Requirements.    Employee acknowledges and agrees that the
following Subsections a through d are included in this Agreement in accordance with the ADEA and the Older Workers Benefit Protection Act (“OWBPA”) and that this Agreement shall not become effective or enforceable until the revocation
period in Subsection b has expired, provided that Employee does not revoke this Agreement during such period: 
  

	 	a.	 Twenty-one (21) Days to Accept.    Employee acknowledges that Employee has been given a period of at least
twenty-one (21) days after receipt of this Agreement to consider whether or not to sign and accept this Agreement. Employee hereby expressly waives Employee’s right to such period if Employee voluntarily signs this Agreement prior to the
expiration of such period. 

  

	 	b.	 Seven (7) Day Revocation.    Employee understands that Employee may revoke this Agreement at any time within seven
(7) days after the date of Employee’s signing indicated below. Employee understands further that this Agreement shall not become effective or enforceable until the revocation period has expired. To revoke this Agreement, Employee must give
written notice which is received by the President of Hillman prior to the expiration of the revocation period. 

  
 Page 4 of 7

  

	 	c.	 Acknowledgments.    Employee acknowledges that Hillman has hereby advised Employee in writing to consult with an attorney
of Employee’s own choosing prior to executing this Agreement. Employee also acknowledges in accordance with the OWBPA that the payments and other consideration set forth in Section 2 above are in addition to anything of value to which
Employee is already entitled. 

  

	 	d.	 “Effective Date”.    The “Effective Date” of this Agreement shall be the eighth (8th) day
following its signing by Employee (after the expiration of the seven (7) day revocation period), provided that Employee does not revoke this Agreement during such period. 

6. Choice of Law and Forum.    Hillman and Employee agree that this Agreement shall be
governed by and construed in accordance with the substantive laws of the State of Ohio. In the event of any dispute between the parties relating in any way to the inducement, performance, breach, validity, interpretation, or enforcement of this
Agreement or of any of the obligations hereunder, the parties agree that the exclusive jurisdiction and forum for any court action as to any such dispute shall be in the state or federal courts for Hamilton County, Ohio; and the parties further
agree that such courts shall have personal jurisdiction over the parties and that the parties hereby waive any objections to such personal jurisdiction. 
 7. No Admission.    The parties acknowledge and agree that neither this Agreement nor the terms hereof nor any action to carry out this Agreement is or shall be construed
as any admission of liability or wrongdoing by any party and each party specifically denies such liability or wrongdoing. 
 8. Entire Agreement.    This Agreement constitutes the complete and entire agreement of the parties with respect to the subject matter hereof. Any and all other promises,
inducements, representations, warranties, or agreements with respect to the subject matter hereof have been superseded hereby and are not intended to survive this Agreement, except that Employee agrees that the provisions of Section 6
(“Confidential Information”) of the Employment Agreement remain in full force and effect and that Employee’s obligations under those provisions survive and are not affected in any way by this Agreement. No amendment or
modification of this Agreement shall be effective unless set forth in writing and signed by Employee and the President of Hillman. 
 9. Acknowledgment of Understanding.    Employee acknowledges that Employee has read this Agreement in its entirety, that Employee understands the terms of this Agreement,
and that Employee is executing this Agreement voluntarily and of Employee’s own free will. 

  
 Page 5 of 7

  

											
	 /s/ Glen E. Hamann
	  		 	 /s/ Ali Fartaj
	 	 9/28/10

	 Witness to Employee
	  		 	 Ali Fartaj
	 		 	 Date

		  		 		 		 		 	
				
		  		 	THE HILLMAN GROUP, INC.	 	
					
	 /s/ Harold J. Wilder
	  		 	By:	 	 /s/ James P. Waters
	 	9/27/10
	 Witness to Hillman
	  		 		 		 		 	Date
		  		 		 	 Printed Name:
	 	 James P. Waters
	 	 
		  		 		 	  
 Title:
	 	  

CFO
	 	 

  
 Page 6 of 7

 Attachment 1 
 Hillman Announces Resignation Of Senior Vice President of Operations, Ali Fartaj 
 CINCINNATI, Sept. 15 /PRNewswire/ — The Hillman Companies, Inc. (the “Company” or “Hillman”), - The Hillman Companies, Inc. announced today that Ali Fartaj, Sr. Vice President of
Operations has decided to resign from his position effective October 22, 2010 to pursue other interests. In the next several weeks we will be working with Mr. Fartaj to have a smooth transition of his responsibilities. Mr. Fartaj
joined Hillman in his current capacity in January 2008. 
 “During his tenure, he has been instrumental in leading the
Operations team through numerous operational improvements, including the implementation of LEAN principles, optimization of supply chain network and processes and incorporation of a higher level of discipline” said Max Hillman, CEO. “We
certainly appreciate Ali’s significant contributions to Hillman and wish him the very best in his future endeavors.” 

Hillman sells to hardware stores, home centers, pet suppliers, mass merchants, and other retail outlets principally in the U.S., Canada,
Mexico, and South America. Their product line includes thousands of small parts such as fasteners and related hardware items, keys, key duplication systems, and identification items, such as tags, letters, numbers and signs. Services offered include
design and installation of merchandising systems and maintenance of appropriate in-store inventory levels. 
 For more
information on the Company, please visit our website at http://www.hillmangroup.com or call investor relations at 800-800-4900 #2084 

  
 Page 7 of 7Service Agreement between the Company and Catalent Pharma Solutions LLC

  
 Exhibit 10.1

 Project Plan and Quotation for GPEx® Feasibility Study of Monoclonal Antibody Candidates h16C3 and 31-1Chi –
Phase A2 
  

			
	 Prepared For:
	 	Andrew Bristol, Neogenix Oncology, Inc. (Neogenix)
	 Prepared By:
	 	Catalent Pharma Solutions, (Catalent)
	 Estimate Number:
	 	NGX.Q.A_012710r5 (Pricing Expires 06.26.10)

 Executive
Summary: 
 The objective of the Project Plan is carry out clonal selection on the Neogenix candidates (h16C3 and 31-1Chi) and deliver
material to Neogenix for evaluation. 
 Assumptions: 

 

	 	•	 	 There will be [ * ]. Phase A1 was committed to by Neogenix and Catalent under NGX08.21.09R1 

 

	 	•	 	 Project will use the cell pool produced in Phase A1. 

  

	 	•	 	 Catalent’s [ * ] will be used to [ * ] during Phase A. 

 

	 	•	 	 Neogenix will be responsible for determining the activity of the molecule produced by Catalent. 

 

	 	•	 	 Catalent will use commercially reasonable efforts to complete the project in a timely manner and meet Neogenix’s project goals.

  

	 	•	 	 This project will be supported by Catalent – Middleton Terms and Conditions (T&C’s) for this Quotation Project Plan.

  

	 	•	 	 At completion of Phase A1, Catalent will store the cells for [ * ] months at no cost to Neogenix. After [ * ] months,
Neogenix will have one of the following options: continue to work with Catalent to complete additional phases of work; pay Catalent to store cells; or have Catalent destroy the cells. 

 

	 	•	 	 Shipping and Handling are not included and will be billed at Catalent’s cost plus [ * ]% (for work beyond Phase A1).

  

	 	•	 	 Pricing is in US dollars and is non-binding until signatures are obtained. 

 

	 	•	 	 Signatures on this document will authorize the execution of Phase A2 of the project. 

 

	 	•	 	 Quoted prices are net of any applicable taxes or withholdings. [ * ] is responsible for payment in full of all taxes, duties or other
deductions as required by law in connection with sums payable to Catalent for services rendered or for sale of a cell line to Neogenix. 

  

	 	•	 	 Catalent reserves the right to charge a [ * ]% per month fee for invoices not paid within [ * ] days of sending an invoice
to Neogenix. 

 Phase A1: Expression Feasibility (two candidates) Competed under separate quotation 

 

			
	 Step
	  	 Description

	[ * ]	  	[ * ] will be used to support Phase A. [ * ] will be used to determine expression level of the pool using a standard provided by Neogenix.
	[ * ]	  	Includes analysis of [ * ].
	[ * ]	  	[ * ].
	Analysis of pooled population	  	[ * ]. Data will be summarized and provided to Neogenix.
		  	

 Upon delivery of the project report, Catalent will store the cells for [ * ] months. During this time
Neogenix may choose to move forward with later phases of development work or enter into an agreement with Catalent for storage of cells at commercially reasonable rates. If neither of these conditions is met Catalent may destroy the cells after
providing Neogenix [ * ] days notice. Catalent will store cells at no cost as long as work involving the cell line continues at Catalent. 
 [ * ] 

  
  

	**	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits information subject to the confidentiality request. Omissions are
designated with brackets containing an asterisk “[ * ]”. As part of our confidential treatment request, a complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 NGX.Q.A_012710r5 - Project Plan and Quotation Page 1 

CONFIDENTIAL 

  
 Phase A2: (Approved by signature
on this quotation) 
  

			
	Clonal selection and screening for the top [ * ] clones	  	[ * ]
	Screening to [ * ]	  	[ * ]
	Deliverables	  	 The Deliverables under Phase A2 of the Quotation shall include [ * ].
 Neogenix will have the option of obtaining clones for a [ * ] day Evaluation Period any time after clonal selection during or after Phase A2. If Neogenix executes this option, no further
evaluation period will granted.

	Top Clone Selection	  	[ * ].
	Project Report	  	A Cell Line Development report in Catalent’s standard format describing [ * ] and documenting [ * ] will be delivered to
Neogenix.

 Phase A Payments: (starting after “go” decision) 

 

			
	 Description of Milestone
	  	 Payment

	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]

 $[ * ]
for first cell line 
 $[ * ] for second cell line (if started concurrently) 

Signature Authorizing Phase A2 

Number of projects moving forward (1 or 2) and
description:                                       
                      
  

							
		
	 For Neogenix Oncology
	 	For Catalent Pharma Solutions LLC.
				
	 By:
	 	  
	 	By:	 	  

				
	 Name:
	 	  
	 	Name:	 	  

				
	 Its:
	 	  
	 	Its:	 	  

				
	 Date:
	 	  
	 	Date:	 	  

 Upon delivery of the project report, Catalent will store the cells for the evaluation period or [ * ] days if an Evaluation Period is not requested by Neogenix. During this time Neogenix may
choose to move forward with later phases of development work, enter into an agreement with Catalent for storage of cells at commercially reasonable rates or enter into a conditional sale agreement with Catalent to gain access to the GPEx® cells lines (with terms to be negotiated). Catalent will store cells at no cost as long as work involving the
cell line continues at Catalent. If none of the above conditions are met, Catalent may destroy the cells after providing Neogenix [ * ] days notice. 

  
  

	**	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

 NGX.Q.A_012710r5 - Project Plan and Quotation Page 2 

CONFIDENTIAL 

  
 Phase B: [ * ]
Development (each project) 
 (A separate quotation will be prepared for each project upon Neogenix’s approval) 

 

			
	[ * ]	  	[ * ]
		
	[ * ]	  	[ * ]
		
	Deliverables	  	 The Deliverables under Phase B of the Quotation will include a detailed description of the [ * ].

 
 If Neogenix does not execute its right to an evaluation period during Phase A2,
Neogenix will have the option of obtaining the [ * ] for a [ * ] day Evaluation Period during or after Phase B. If Neogenix executes this option, no further evaluation period will granted.

 

			
	 Description of Milestone
	  	 Payment

	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]
	 [ * ]
	  	[ * ]

 Total for Phase B: [ *
] 
 Summary of other options: [ * ] only = [ * ] with a flat fee of [ * ] for consumables 

A separate quote will be provided for approval if Neogenix decides to move forward with Phase B. 
 Catalent-Middleton: 
  

			
	 Catalent-Middleton Contact Information:
  

BD contact : Rob Gustines, Account Director
  

Phone number (direct): 919-465-8139
  

Phone number (mobile) : 919-803-9595
  

email: rob.gustines@catalent.com
  
	  	  
 8137 Forsythia Street

 
 Middleton, WI 53562

 
 608-824-9920

 
 www.gpextech.com

 
 www.catalent.com

 

	  
 Client Contact Information:

 
 Client contact name: Andy Bristol, Ph.D.

 
 Phone number (direct): 240-314-0596

 
 email: abristol@neogenix.us
	  

  
  

	**	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

 NGX.Q.A_012710r5 - Project Plan and Quotation Page 3 

CONFIDENTIAL 

  
 Catalent Pharma
Solutions, LLC - Middleton, Wisconsin Facility - Terms and Conditions 
 A. Expiration. This Quotation becomes binding if signed and
delivered by both parties. The Terms and Conditions set forth herein shall apply exclusively to Phase A2 and B of this Quotation, NGX.Q.A_012710r5, but each of Phase A2 and B shall be approved and agreed upon by signature of the parties on separate
and phase-specific Authorization signature pages. 
 B. Audits. Client may conduct one quality assurance facility audit per year at no
cost. Additional audits will be invoiced separately at the current rate for such services. 
 C. Regulatory Inspections. Catalent will
promptly notify Client of any regulatory inspections directly relating to the Project. Client accepts reasonable and documented costs charged by a regulatory authority for such inspections. 
 D. Amendments to Quotations/Price Changes. Any material change in the details of this Quotation or the assumptions upon which the Quotation is based may require changes in the pricing and time
lines, and shall require a written amendment to the Quotation (a “Change Order”). Each Change Order shall detail the requested changes to the applicable task, responsibility, duty, pricing, time line or other matter. The Change Order will
become effective upon the execution of the Change Order by both parties, and Catalent will be given a reasonable period of time within which to implement the changes. Both parties shall act in good faith and promptly when considering a Change Order
requested by the other party. Catalent may revise the prices provided in this Quotation (i) if Client’s requirements or any Client-provided information is inaccurate or incomplete; (ii) if Client revises Catalent’s
responsibilities or the Project specifications, instructions, procedures, assumptions, processes, test protocols, test methods or analytical requirements; or (iii) for such other reasons set forth in this Quotation. 

E. Payments. Catalent will invoice Client as set forth in this Quotation. Catalent charges a late payment fee of [ * ]% per month
for payments not received by the date specified in this Quotation (or if no date is specified, within [ * ] days of invoice date). Failure to bill for interest due shall not be a waiver of Catalent’s right to charge interest.

 F. Taxes. All sales, use, gross receipts, compensating, value-added or other taxes, duties, licenses or fees (excluding
Catalent’s net income and franchise taxes) assessed by any tax jurisdiction arising from the Project are the responsibility of [ * ], whether paid by Catalent or Client. To the knowledge of Catalent, the payments to be made by the
Client to Catalent under the Quotation are not subject to sales tax or use tax. 
 G. Hazardous Materials. Client warrants to Catalent
that no specific safe handling instructions are applicable to any Client-supplied materials, except as disclosed to Catalent in writing by the Client in sufficient time for review and training by Catalent prior to delivery. Where appropriate or
required by law, Client will provide a Material Safety Data Sheet for all Client-supplied materials and finished product. 
 H. Delivery.
All products and other materials provided by Catalent are delivered EXW (Incoterms 2000) Catalent’s facilities and the title shall pass to Client upon such delivery. If Catalent provides storage services, title and risk of loss shall pass to
Client upon transfer to storage. 
 I. Limitations of Liability. CATALENT’S TOTAL LIABILITY UNDER PHASE A2 and B OF THIS QUOTATION
SHALL IN NO EVENT EXCEED [ * ]. CATALENT’S LIABILITY UNDER THIS QUOTATION FOR ANY AND ALL CLAIMS FOR LOST, DAMAGED OR DESTROYED API OR CLIENT-SUPPLIED MATERIALS, WHETHER OR NOT INCORPORATED INTO FINISHED PRODUCT, SHALL NOT EXCEED
[ * ]. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF PERFORMANCE UNDER THIS QUOTATION, INCLUDING WITHOUT LIMITATION LOSS OF REVENUES, PROFITS OR DATA, WHETHER IN
CONTRACT OR IN TORT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 J. Confidentiality. The Mutual
Confidentiality and Non-Disclosure Agreement dated April 12, 2007 entered into by the parties (at such time, Catalent was named Cardinal Health PTS, LLC) (the “NDA”) remains in full force and effect. 

K. Intellectual Property. For purposes hereof, “Client IP” means all intellectual property and embodiments thereof owned by or licensed
to Client as of the date hereof or developed by Client other than in connection with the Project; “Catalent IP” means all intellectual property and embodiments thereof owned by or licensed to Catalent as of the date hereof or developed by
Catalent other than in connection with the Project; “GPEx® Technology” means Catalent’s proprietary gene product expression technology for the expression of proteins through retrovector transduction of mammalian cell lines;
“Invention” means any intellectual property developed by either party in connection with the Project; “API Inventions” means any Invention that relates exclusively to the Client IP or Client’s

  
  

	**	Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits information subject to the confidentiality request. Omissions are
designated with brackets containing an asterisk “[ * ]”. As part of our confidential treatment request, a complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

  

			
	Catalent_Neogenix Terms and Conditions_ NGX.Q.A_012710r5_August 2010	  	Page 1 of 5
		  	

 
patented API; and “Process Inventions” means any Invention, other than an API Invention, that relates exclusively to the Catalent IP or relates to developing, formulating,
manufacturing, filling, processing, packaging, analyzing or testing pharmaceutical products generally. All Client IP, the cDNA encoding the antibody that Client would like to produce (“Client cDNA”) and all API Inventions shall be owned
solely by Client and no right therein is granted to Catalent under this Quotation except for use in performing the Project. All Catalent IP and Process Inventions shall be owned solely by Catalent and no right therein is granted to Client under this
Quotation. For the avoidance of doubt, under this Quotation, Catalent shall solely own any Inventions related to the GPEx® Technology including, but not limited to, (i) improvements relating to cell engineering processes (e.g., gene
insertion and expression in mammalian cells and cell culture and protein purification processes), (ii) all vectors for gene transduction and expression, and (iii) intellectual property rights to the foregoing; no rights to any such
Inventions or intellectual property rights related to the GPEx® Technology are granted to Client under this Quotation except as may be agreed to in writing by the parties in a subsequent cell line sale or other agreement. Client shall have the
right to access all deliverables under the Quotation and shall retain its rights incorporated in the deliverables. 
 It is understood and
agreed that ownership and control of any cell lines included as a deliverable shall not be transferred to Client until Catalent and Client have negotiated and entered into a Cell Line Sale Agreement (or similar license agreement) and the payment for
the cell lines have been received by Catalent from Client. Catalent’s rights to the deliverables are limited to performing work authorized by Client, or destroying the deliverables if Client abandons the project or directs Catalent to destroy
the deliverables. The parties shall cooperate to achieve the allocation of rights to Inventions anticipated herein and each party shall be solely responsible for costs associated with the protection of its intellectual property. 

Catalent shall notify Client during the term of the Quotation, if: any Catalent patents or intellectual property directly relating to GPEx technology
become involved in any interference or opposition proceeding. 
 Catalent hereby grants to Client and its Affiliates the right to evaluate, with
the limited right to transfer the deliverables under Phase A2 and B of the Quotation and to perform any necessary testing of the deliverables under Phase A2 and B of the Quotation for a period of [ * ] days following the delivery of
the last deliverable to Client (the “Evaluation Period”). Such evaluation process will assess the biological activity of cell culture supernatant, partially purified or purified protein using four assays: [ * ]. Client will
also be eligible to transfer the engineered cell line(s) to allow for third party upstream and/or downstream process development to optimize cell line growth conditions for improvement of antibody yield, the results of which will be used in
Client’s consideration to pursue a Cell Line Sale/Licensing Agreement with Catalent, provided that Client provides Catalent with access to the general project plan and resulting data, and it is understood that this transfer does not permit the
cell line to be used in any cGMP activities, including master cell bank manufacturing. Such Evaluation Period does not entitle Client or its Affiliates to undertake any additional clinical research, clinical development, manufacturing,
commercialization or any other use of the deliverables under the Quotation. If Client does not continue with Catalent on the project at the end of the period of the Evaluation Period, then in such event, Client shall destroy all deliverables under
the Quotation in its custody or control and warrant the destruction of all cells transferred to third parties and provide a certificate of destruction to Catalent within [ * ] days of the end of the Evaluation Period. 

L. Warranties. 
 Catalent hereby
warrants, represents and covenants to Client that: 
 To the best of Catalent’s knowledge, as of the executed date of the
Quotation, there are no third party intellectual property rights that may be asserted against Catalent or Client claiming that the use by Catalent or Client of the Catalent IP under the Quotation constitutes, has constituted or will constitute an
infringement thereof or a violation or breach of a contract with a third party; 
 As of the date of the Quotation, there is no
pending litigation which alleges that the use of Catalent IP has infringed or misappropriated any of the intellectual property of any third party; 
 Catalent is the owner of or controls the Catalent IP and to the best of its knowledge has the right to grant Client the rights granted Client under the Quotation, and will not during the term of the
Quotation, grant any rights to any third party that would adversely affect the rights granted to Client under the Quotation; 

As of the date of the Quotation, the Catalent IP are free and clear of any encumbrance, lien, mortgage, charge, or to Catalent’ best
knowledge restriction or liability of any kind whatsoever, whether equitable or legal; and 
 As of the date of the Quotation,
none of the Catalent IP are involved in any interference or opposition proceeding. 
 All deliverables that Catalent provides to
Client under the Quotation shall have the characteristics described in the applicable reports provided by Catalent to Client and such deliverables and replacement materials shall be in compliance with the applicable project plan. 

  
  

	**	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  

			
	Catalent_Neogenix Terms and Conditions_ NGX.Q.A_012710r5_August 2010	  	Page 2 of 5
		  	

  
 Catalent will perform the Project in
accordance with the written specifications and Project instructions expressly set forth or referenced in this Quotation, and in compliance with all applicable laws and regulations and [ * ] current Good Manufacturing Practices, as
applicable. Catalent shall perform the Services using development methods and techniques and record keeping practices that are in compliance with the applicable project plan. THE WARRANTIES SET FORTH IN THIS ARTICLE ARE THE SOLE AND EXCLUSIVE
WARRANTIES MADE BY CATALENT TO CLIENT, AND CATALENT MAKES NO OTHER REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY KIND WHATSOEVER, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.

 Catalent understands that the Client Cell Lines is experimental in nature and may have hazardous properties, and Catalent agrees that it
shall use the Client Cell Lines in strict accordance with the Proposal and with Client’s written instructions and that Catalent shall not use the Client Cell Lines in humans or animals. 
 EXCEPT AS EXPRESSLY SET FORTH IN THE QUOTATION, CLIENT DOES NOT MAKE ANY REPRESENTATION OR WARRANTY TO CATALENT OF ANY NATURE, EXPRESS OR IMPLIED, THAT THE CLIENT CELL LINES WILL BE USEFUL FOR, OR ACHIEVE
ANY PARTICULAR RESULTS AS A RESULT OF ANY USE THEREOF BY CATALENT PURSUANT TO THE QUOTATION AND Client HEREBY DISCLAIMS ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. 

M. Client Obligations. Unless otherwise agreed to by the parties in writing, Client is solely responsible to (i) provide complete and
accurate scientific data regarding the Project; (ii) if applicable, review and approve all in-process and finished product test results to ensure conformity of such results with the product specifications, regardless of which party is
responsible for finished product release; (iii) prepare all submissions to regulatory authorities; and (iv) perform such other obligations of Client set forth in this Quotation. Catalent will make commercially reasonable efforts to assist
Client with all regulatory matters relating to this Quotation, at Client’s request and at Client’s expense. 
 N. Indemnification.

 Client will indemnify Catalent, its affiliates and their respective directors, officers, employees and agents against any third-party
claim arising directly or indirectly from (i) the manufacture, promotion, marketing, distribution or sale of, or use of or exposure to, the product, API and Client-supplied materials that are the subject of the Project; (ii) the gross
negligence or willful misconduct of Client; (iii) the breach of this Quotation by Client; or (iv) the use of any intellectual property provided by Client to Catalent; except to the extent any of the foregoing arise from the negligence,
willful misconduct or breach of this Quotation by any Catalent indemnified party. Catalent will indemnify Client, its affiliates and their respective directors, officers, employees and agents against any third-party claim arising directly or
indirectly from the negligence or willful misconduct of Catalent or the breach of this Quotation by Catalent; except to the extent any of the foregoing arise from the negligence, willful misconduct or breach of this Quotation by any Client
indemnified party. In the event Catalent seeks indemnification under this paragraph N, Catalent shall (a) notify Client of a claim as soon as reasonably practicable after it receives notice of the claim, (b) provided that Client is not
contesting the indemnity obligation, permit Client to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration), and (c) cooperate as requested (at Client’s
expense) in the defense of the claim; but provided always that neither party may settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding or make any admission as to liability or fault
without the prior express written permission of the other client, such consent not to be unreasonably withheld or delayed. 
 During the term of
the Quotation and thereafter, Catalent will indemnify Client, its affiliates, and their respective officers, directors, employees, consultants and agents against any and all liability, damage, loss or expense (collectively, “Losses”) in
connection with any third-party claim arising directly or indirectly from (i) any material breach or any alleged breach of Catalent’ representations, warranties, and covenants set forth in this Quotation or these Terms and Conditions,
(ii) the gross negligence or willful misconduct of Catalent; or (iii) the use of any intellectual property provided by Catalent to Client, except to the extent that such Losses result from the negligence or intentional misconduct of any
Client indemnified party. In the event Client seeks indemnification under this paragraph N, Client shall (a) notify Catalent of a claim as soon as reasonably practicable after it receives notice of the claim, (b) provided that Catalent is
not contesting the indemnity obligation, permit Catalent to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration), and (c) cooperate as requested (at Catalent’s
expense) in the defense of the claim; but provided always that neither party may settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding or make any admission as to liability or fault
without the prior express written permission of the other client, such consent not to be unreasonably withheld or delayed. 

  
  

	**	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  

			
	Catalent_Neogenix Terms and Conditions_ NGX.Q.A_012710r5_August 2010	  	Page 3 of 5
		  	

  
 O. Catalent Insurance. Catalent
shall, at its own cost and expense, obtain and maintain in full force and effect the following insurance during the Term: (A) Commercial General Liability Insurance with a per-occurrence limit of not less than [ * ]; (B) Drug
Products and Completed Operations Liability Insurance with a per-occurrence limit of not less than [ * ]; (C) Workers Compensation and Employers Liability Insurance, with statutory limits for Workers Compensation and Employers
Liability limits of not less than [ * ] per accident; and (D) Professional Services Errors & Omissions Liability Insurance with per-claim and aggregate limits of not less than [ * ]. The parties hereby
acknowledge and agree that Catalent may self-insure all or any portion of the required insurance. In the event that any of the required policies of insurance are written on a claims made basis, then such policies shall be maintained during the
entire Term and for a period of not less than [ * ] years following the expiration or termination of this Agreement. Catalent shall obtain a waiver from any insurance carrier with whom Catalent carries Workers’ Compensation
insurance releasing its subrogation rights against Client. Catalent shall furnish to Client a certificate of insurance or other evidence of the required insurance and additional insured status as soon as practicable after the Effective Date and
within [ * ] days after renewal of such policies. Each insurance policy which is required under this Agreement, other than self-insurance, shall be obtained from an insurance carrier with an A.M. Best rating of at least A- VII.

 P. Client Insurance. Client shall, at its own cost and expense, obtain and maintain in full force and effect the following insurance
during the Term: (A) Commercial General Liability Insurance with a per occurrence limit of not less than an amount equivalent to [ * ]; (B) Drug Products and Completed Operations Liability Insurance (including coverage for
Drug Products used in clinical trials) with a per occurrence limit of not less than an amount equivalent to [ * ]; (C) Workers Compensation and Employers Liability Insurance with statutory limits for Workers Compensation and
Employers Liability limits of not less than an amount equivalent to [ * ] per accident; and (D) All Risk Property Insurance, including transit coverage, in an amount equal to [ * ]. The parties hereby acknowledge and
agree that Client may self-insure all or any portion of the above-required insurance. Client shall maintain levels of insurance or self insurance sufficient to meet its obligations under this Agreement. In the event that any of the required policies
of insurance are written on a claims made basis, then such policies shall be maintained during the entire Term and for a period of not less than [ * ] years following the expiration or termination of this Agreement. Client shall not
seek reimbursement for any property claim or portion thereof that is not fully recovered from Client’s Property Insurance policy. CPS, Inc. and its Affiliates shall be named as additional insureds under the Drug Products and Completed
Operations Liability insurance policies with respect to the products and completed operations outlined in this Agreement. Client shall furnish certificates of insurance evidencing the required insurance policies and additional insured status to
Catalent as soon as practicable after the Effective Date and within [ * ] days after renewal of such policies. Each insurance policy that is required under this Agreement shall be obtained from an insurance carrier with an A.M. Best
rating of at least A- VII. 
 Q. Force Majeure. Neither party will be liable for any failure to perform or for delay in performance
resulting from any cause beyond its reasonable control, including without limitation acts of God, fires, floods or weather, strikes or lockouts, factory shutdowns, embargoes, wars, hostilities or riots, or shortages in transportation. If the cause
continues unabated for [ * ] days, then both parties shall meet to discuss and negotiate in good faith what modifications to this Quotation should result from such cause. 
 R. Use and Disposal. Catalent shall use the Client Cell Lines solely to perform the Services and for no other purpose, and Catalent shall store and use the Client Cell Lines in accordance with all
applicable laws and regulations. Catalent shall use best efforts to keep the Client Cell Lines secure and safe from loss, damage, theft, misuse and unauthorized access. Catalent shall not analyze or reverse engineer the Client Cell Lines in any
manner. Catalent shall not distribute the Client Cell Lines to any Affiliate or Third Party, and shall not use the Client Cell Lines for any research or commercial purpose other than to perform the Services. Client represents and warrants to
Catalent that Client will hold, use and/or dispose of products and other materials provided by Catalent in accordance with all applicable laws, rules and regulations, including as they relate to use in humans. Client grants Catalent full authority
to use any Client-supplied materials for purposes of the Project. 
 S. Record Retention. Catalent will document in a manner appropriate
for purposes of filing regulatory filings for products with applicable regulatory authorities in [ * ] and retain batch, laboratory and other technical records for the minimum period required by applicable law. Subject to paragraph K
hereof, Catalent shall provide Client the right to inspect and copy such records to the extent reasonably required for the performance of its obligations under this Agreement; provided, that, Client agrees to not use such records or
information except to the extent otherwise permitted herein. 

  
  

	**	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  

			
	Catalent_Neogenix Terms and Conditions_ NGX.Q.A_012710r5_August 2010	  	Page 4 of 5
		  	

  
 T. Independent Contractor. The
relationship of the parties is that of independent contractors and not of joint venturers, co-partners, employer/employee or principal/agent. 

U. Publicity. Neither party will make any press release or other public disclosure regarding this Quotation or the transactions contemplated
hereby without the other party’s express prior written consent, except as required by applicable law, by any governmental agency or by the rules of any stock exchange on which the securities of the disclosing party are listed, in which case the
party required to make the press release or public disclosure shall provide copies of the disclosure reasonably in advance of such filing or other disclosure for the non-disclosing Party’s prior review and comment and shall use commercially
reasonable efforts to obtain the approval of the other party as to the form, nature and extent of the press release or public disclosure prior to issuing the press release or public disclosure. 

V. Amendment & Precedence. These Terms and Conditions constitute a part of the Quotation to which they are attached (collectively,
“this Quotation”); provided, that these Terms and Conditions supersede any conflicting terms and conditions set forth in the Quotation to which they are attached or any other document, including Client purchase order. This
Quotation, together with the NDA, constitutes the entire understanding between the parties, and supersedes any contracts, agreements or understandings (oral or written) of the parties, with respect to the Project. No term of this Quotation may be
amended except upon written agreement of both parties. 
 W. Waiver; Severability; Third Parties. The failure on the part of a party to
exercise or enforce any rights conferred upon it hereunder shall not be deemed to be a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times hereafter. If any term of this Quotation is declared invalid
or unenforceable by a court or other body of competent jurisdiction, the remaining terms of this Quotation will continue in full force and effect. This Quotation shall not confer any rights or remedies upon any person or entity other than the
parties named herein and their respective successors and permitted assigns. 
 X. Assignment. [ * ] This Agreement shall be
binding upon the successors and permitted assigns of the parties and the name of a party appearing herein shall be deemed to include the names of such party’s successors and permitted assigns to the extent necessary to carry out the intent of
the Quotation. Any assignment not in accordance with this paragraph W shall be null and void. Catalent may not assign or delegate to any subcontractor any of Catalent’s obligations under the Quotation or these Terms and Conditions, unless
Client has given its prior written consent thereto. 
 Y. Dispute Resolution. If a dispute arises between the parties in connection with
this Quotation, the respective presidents or Senior Executives of Catalent and Client shall first attempt to resolve the dispute. If such parties cannot resolve the dispute, such dispute shall be resolved in the jurisdiction of the defendant party
by binding arbitration in accordance with the then existing commercial arbitration rules of The CPR Institute for Dispute Resolution, 366 Madison Avenue, New York, NY 10017. 
 Z. Termination. Either party may terminate the Quotation at any time and for any reason, by giving the other party written notice thereof. In the event of such termination by Client, Client shall
pay [ * ]. Either party may terminate this Quotation immediately without further action if (A) the other party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for or consents to the
appointment of a receiver, administrative receiver, trustee or administrator, makes an assignment for the benefit of creditors, or suffers or permits the entry of any order adjudicating it to be bankrupt or insolvent and such order is not discharged
within [ * ] days or takes any equivalent or similar action in consequence of debt in any jurisdiction; or (B) the other party materially breaches any of the provisions of this Quotation, and such breach is not cured within
[ * ] days after the giving of written notice requiring the breach to be remedied. 
 AA. Effect of Termination; Survival.
Upon the expiration or termination of this Quotation, each party shall return to the other party (or, if so requested in writing, destroy and provide a certificate of destruction signed by the respective party’s Head of Research and Development
attesting to such destruction) all tangible embodiments, and render inaccessible or useless all electronic embodiments, of the other party’s confidential information, Client Cell Lines, and other items belonging to the other party. The rights
and obligations of Client and Catalent in Articles I, J, K, L, N, O, R, T, V, X, Z and AA of these Terms and Conditions shall survive termination or expiration of this Quotation. 
 BB. Governing Law. This Quotation shall be governed by and construed under the laws of the State of New Jersey, USA, excluding its conflict of law provisions. The United Nations Convention on
Contracts for the International Sale of Goods shall not apply to this Quotation. 

  
  

	**	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions. 

  

			
	Catalent_Neogenix Terms and Conditions_ NGX.Q.A_012710r5_August 2010	  	Page 5 of 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]